Sign in with Google. Opens in new tab
bullish

ABLBio

ABLBio (298380 KS): Continued License Out Deals and Milestone Payment Realization to Feed Pipeline

348 Views07 Apr 2025 15:13
​ABLBio partners with GSK to develop CNS treatments using Grabody-B, potentially receiving up to £2.075B in milestone payments and royalties. Earlier deal with Sanofi is unlocking milestone payments.
What is covered in the Full Insight:
  • Introduction to ABL Bio and its recent licensing deal with GSK
  • Details and implications of the GSK agreement
  • Partnerships and progress with Sanofi and Compass Therapeutics
  • Ongoing clinical trial developments and pipeline advancements
  • Financial outlook and strategic positioning of ABL Bio
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
chart-bar
Logo
Top Quartile
Tina Banerjee
Global Healthcare Analyst
Health CareEquity Bottom-UpThematic (Sector/Industry)
Price Chart(Sign Up to Access)
analytics-chart
  • ABLBio (298380 KS): Continued License Out Deals and Milestone Payment Realization to Feed Pipeline
    07 Apr 2025
x